Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05190627
Other study ID # LORALAM
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 1, 2021
Est. completion date December 30, 2023

Study information

Verified date January 2022
Source Institut d'Investigació Biomèdica de Bellvitge
Contact Mar Chicote, PM
Phone 0034932607689
Email ufip@bellvitgehospital.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

INTRODUCTION: LAM is a rare and lethal disease characterized by progressive cystic lung destruction. Inhibition of mTOR with rapamycin is the current standard of care (SOC), which can slow-down disease. Plasma major histamine metabolite (Methylimidazoleacetic acid [MIAA]) is increased in LAM. Loratadine is a histamine receptor antagonist (HR1), which inhibits LAM cell proliferation. Therefore, a novel phase-II clinical trial for assessing safety and potential benefits of loratadine in LAM has been initiated. METHODS: LORALAM clinical trial, phase-II, double-blind, randomized, placebo controlled, parallel-group, multicentre study initiates recruitment in July 2020. Enrollment plan includes 62 subjects with LAM on treatment with rapamycin ≥3 months, randomized 1:1 to add oral loratadine 10mg/day or placebo, once daily, for 52 weeks. Recruitment will end in June 2021. The primary endpoints are 1) to assess the safety profile of loratadine associated with rapamycin, 2) lung function decline after 52 weeks of treatment. The secondary endpoints are a) quality of life and progression free-survival time, b) changes in the established LAM serum biomarker VEGFD, c) the utility of MIAA for monitoring disease progression and biological treatment effect. ETHICS AND DISSEMINATION: The study will be carried out in accordance with Good Clinical Practice guidelines, Declaration of Helsinki principles, and each ethical committee. This clinical trial contemplates the possibility of increasing the number of centers and including patients from patient support groups (LAM foundation, AELAM)


Description:

Lymphangioleiomyomatosis (LAM) is a rare and lethal lung disease affecting almost exclusively women of childbearing age and characterized by progressive cystic lung destruction. LAM results from germline and somatic loss-of-function mutations in the tuberous sclerosis complex 1 and 2 genes (TSC1/2), and therefore diseased cells show abnormal activation of the mechanistic target of rapamycin (mTOR). Inhibition of mTOR with rapamycin (also known as sirolimus) is the current standard of care. However, this therapy does not fully kill LAM cells, shows variable tolerability and treatment answer. Therefore, sirolimus has slowed-down disease progression but young patients still need lung transplantation despite treatment. In addition, LAM diagnosis and clinical monitoring is also challenging due to the heterogeneity of symptoms and insufficiency of non-invasive tests. Here, guided by comprehensive preclinical data obtained in the context of a Spanish research network for LAM, and with the support of the national Association of LAM patients (AELAM), the investigators propose a phase-II clinical trial for assessing if the tricyclic antihistamine loratadine is effective in slowing the progression of lung disease in LAM. Loratadine is an histamine receptor 1 (HR1) antagonist, widely used for allergic process, that also acts through different intracellular signaling, including Akt/MITF and PKCBII-tyrosine kinase. Recent studies have demonstrated that co-treatment with loratadine sensitize KBV20C resistant cells to vincristine, which improve the onco-therapeutical effect. The primary study objective is to assess the safety profile of loratadine 10 mg/day associated with the current standard treatment (sirolimus) and its potential benefit abrogating the lung function decline after 52 weeks of treatment. The secondary objectives include; a) an assessment of quality of life and progression free-survival time, and, b) to determine the clinical usefulness of the major histamine-derived metabolite methylimidazoleacetic acid (MIAA) for monitoring of disease progression and biological treatment effect.


Recruitment information / eligibility

Status Recruiting
Enrollment 62
Est. completion date December 30, 2023
Est. primary completion date December 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 1. Written informed consent consistent with GCP and local laws signed prior to entry into the study. 2. Patients with LAM and > 18 years-old with: - FEV1 > 35% and DLCO > 20% - Oxygen saturation (SpO2) > 85% by pulse oximetry while breathing ambient air at rest - Patients with a definite diagnosis consistent with LAM prior to screening based on International consensus criteria within 10 years prior to randomization - HRCT within 12 months prior to randomization with central reading demonstrating a radiological pattern suggesting LAM and some other criteria for initiating sirolimus (symptoms, FEV1 decline or the presence of abdominal lynphangioleiomiomas). Exclusion Criteria: - Concomitant use of other HR1 antagonist - Hypersensitivity to HR1 antagonists - Current smoker or ex-smoker having quit smoking < 4 months prior to firs screening visit - Use of systemic immunosuppressants or chemotherapy within 30 days of screening. - Receiving oral corticosteroids>15mg/day, vasodilator therapies for pulmonary hypertension (e.g., bosentan), unapproved and/or investigational therapies for LAM or administration of such therapies within 4 weeks of initial screening. - At baseline/screening visit, values of liver transaminases above 3 times upper limit, alkaline phosphatase above 2.5 times upper limit, or bilirubin above 1.5 times upper limit - Creatinine clearance (CrCl)<60ml/min (determined by Cockcroft-Gault Equation) at baseline/ screening visit. - Patients treated with strong inhibitors and inducers of CYP either during the study or 14 days prior to enrolment in the study: antifungals (e.g., ketoconazole, itraconazole), clarithromycin, telithromycin, cobicistat, protease inhibitors (e.g., atazanavir, ritonavir, and saquinavir) and grapefruit juice, phenytoin, carbamazepine, barbiturates, rifampin. - Current allergic asthma or other major allergic diseases that requires different daily anti- histaminic treatment. - History of coexistent and clinically significant (in the opinion of the Investigator) chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma, inadequately treated sleep- disordered breathing, or any clinically significant pulmonary diseases other than LAM.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Loratadine
Loratadine 10mg/day added to rapamycin for 12 months
Placebo 10mg/day added to rapamycin for 12 months
Placebo in the same type of capsule than the experimental drug

Locations

Country Name City State
Spain Hospital Vall d'Hebron Barcelona
Spain University Hospital of Bellvitge Hospitalet de Llobregat Barcelona
Spain Hospital La Princes Madrid
Spain Hospital Puerta de Hierro Madrid
Spain Hospital Marqués de Valdecillas Santander
Spain Hospital Virgen del Rocío Sevilla

Sponsors (1)

Lead Sponsor Collaborator
Institut d'Investigació Biomèdica de Bellvitge

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Treatment-Emergent Adverse Events (safety) of loratadine in combination with sirolimus after 52 weeks of treatment To compare the incidence of adverse events in LAM patients treated with sirolimus and loratadine versus sirolimus alone. Any adverse event related to both drugs, including nausea, diarrhea, stomach discomfort, vomiting, headache and liver hipertransaminasemia, will be evaluated. 52 weeks
Secondary To evaluate the effect of loratadine associated with sirolimus on quality of life measured by the Saint George's Questionnaire The Saint George's Questionnaire is one of the most validated questionnaires in respiratory diseases that evaluates three dimensions; symptoms, activity and disease impact, and the total score ranges from 0 (worse situation) to 100 (best situation). 52 weeks
Secondary Study-drug discontinuation To compare the rate of study-drug discontinuation during the study in both arms 52 weeks
Secondary Serum levels of sirolimus Analyzing the number of patients that maintain the serum levels of sirolimus on window range that is considered therapeutic and safe (5-15 pg). 52 weeks
Secondary To evaluate the effect of loratadine associated with sirolimus on progression-free survival time Progression-free survival time, which will be considered when some of these events are present: FEV1 decrease > 10%, DLCO decrease > 15%, lung transplant, death. 52 weeks
Secondary To evaluate the effect of loratadine associated with sirolimus on hospitalization rate Hospitalization. Registration of any cause of hospitalization. 52 weeks
Secondary To evaluate the effect of loratadine associated with sirolimus on serum biomarkers Serum biomarkers: measuring changes on the single established biomarker to date (VEGF-D) 52 weeks
See also
  Status Clinical Trial Phase
Completed NCT01687179 - Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis Phase 1
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT00552955 - Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
Unknown status NCT00490789 - Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Phase 2
Not yet recruiting NCT05087134 - Characterizing LAM With 11C-Choline PET/CT Early Phase 1
Completed NCT02009241 - Pulmonary Rehabilitation in Lymphangioleiomyomatosis N/A
Completed NCT05323370 - Lymphangioleiomyomatosis, a Study on Cathepsin K
Completed NCT02859194 - The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients N/A
Completed NCT01353209 - Letrozole for Lymphangioleiomyomatosis Phase 2
Completed NCT03253913 - Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial Phase 2
Recruiting NCT02432560 - Safety and Durability of Sirolimus for Treatment of LAM
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Active, not recruiting NCT01552434 - Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease Phase 1
Recruiting NCT04577937 - Sleep Patterns in Patients Affected by Lymphangioleiomiomatosis N/A
Completed NCT00005906 - Treatment With Octreotide in Patients With Lymphangioleiomyomatosis Phase 2
Recruiting NCT01799538 - Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis Phase 1/Phase 2
Completed NCT00989742 - Doxycycline In Lymphangioleiomyomatosis (LAM) Phase 4
Recruiting NCT06160310 - Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Enrolling by invitation NCT05727852 - Breath Analysis and Arterial Stiffness in Patients With Respiratory Diseases
Completed NCT03131999 - LAM Pilot Study With Imatinib Mesylate Phase 1/Phase 2

External Links